Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I

NCT02354976 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02354976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02354976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2015
Completion date
May 26, 2016
Enrollment
78 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia, non-alcoholic fatty liver disease (nafld